Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Merck Serono Aims to Become Leading Company in Oncology: Dr Wein
May 3, 2010
- Chuikyo Members Call For Penalties for Fraudulent Practice
May 3, 2010
- JPMA Removes All MTPC Representatives from Executive Positions
May 3, 2010
- Japan Should Accept More Overseas Clinical Data: Mr Dunoyer
May 3, 2010
- Astellas Launches Prograf in India
May 3, 2010
- Positive Efficacy Data Obtained for MDV3100 in PI, PII: Astellas, Medivation
May 3, 2010
- Eisai Licenses Cinitapride from Almirall in China
May 3, 2010
- Lawmakers to Include Lifting of Ban on Online Sales of Drugs in DPJ Manifesto
May 3, 2010
- Sanofi-aventis Licenses New Diabetes Treatment from CureDM Sign
May 3, 2010
- No Call for Lifting of Ban on Kongo Shinryo from DPJ Lawmakers
May 3, 2010
- Kowa, Nitto Denko to Codevelop Transdermal Donepezil Patches
May 3, 2010
- Sato: Patch Test Tape for Allergic Skin Diseases
May 3, 2010
- Nippon Kayaku, Teva-Kowa to Develop G-CSF Biosimilar
May 3, 2010
- Medipolis Completes Cancer Radiotherapy Center in Kagoshima
May 3, 2010
- Biosimilar for EPO Priced at 77% of the Original Drug
May 3, 2010
- Astellas' VESIcare Website Contains “Unsubstantiated Superiority Claims” FDA
May 3, 2010
- Fentos Tape Approved in Japan: Hisamitsu, Kyowa Kirin
May 3, 2010
- Sanofi-aventis Aims at Double-Digit Growth Rate for 4 Years in a Row
May 3, 2010
- Biomedical Cluster Kansai Changes Its Operation Systems
April 26, 2010
- Only 12.6% of the Elderly Aware of Pneumococcal Vaccines
April 26, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…